AllianzGI Partners with The Sea Cleaners to Combat Plastic Pollution in the World’s Oceans
-
The Sea Cleaners’ focus on ocean preservation and pollution
education a natural fit with AllianzGI’s commitment to Sustainability -
Five-year partnership will offer engagement opportunities for
AllianzGI’s clients and colleagues, and support the launch of ‘The
Manta’, a revolutionary new ship, combining several renewable
technologies to reduce its carbon footprint, capable of collecting
10,000 tonnes of plastic macro-waste a year
LONDON–(BUSINESS WIRE)–Allianz Global Investors, one of the world’s leading active investment
managers, announced today that it has entered into a five-year
partnership with The Sea Cleaners, a new project designed to combat
plastic pollution in the world’s oceans. AllianzGI’s support for The Sea
Cleaners is a natural fit with the firm’s commitment to Sustainable
investing, with the partnership also set to open up new engagement
opportunities for AllianzGI’s colleagues and clients, many of whom are
already actively working to combat plastic waste.
Partnering with AllianzGI will support the development of ‘The Manta’,
The Sea Cleaners’ giant new waste collection ship. Measuring in at 70
metres long, 49 metres wide and 61 metres high, The Manta is expected to
take to the seas in 2022. It will use state-of-the-art technology to
collect plastic macro-debris in high density areas like coastlines and
estuaries before they break up and disperse and irreversibly damage
bio-diversity. As well as mass collecting discarded plastic, the ship,
powered by wind turbines, solar panels and automized rigs, will conduct
cutting-edge scientific research, with The Sea Cleaners providing open
source data. One energy recovery unit will also convert non-recyclable
plastics to run the ship and the on-board factory.
On land, The Sea Cleaners work to raise awareness among future
generations of the harm caused by plastic pollution through a wide range
of activities in schools and fairs. As part of this new partnership,
AllianzGI colleagues will have the chance to participate in events with
The Sea Cleaners’ team focused on reducing plastic pollution and leaders
from The Sea Cleaners will attend and support AllianzGI’s range of
Sustainability events.
Thorsten Heymann, Global Head of Strategy at AllianzGI, said:
”A shocking 9 million tonnes of plastic are dumped in the ocean every
year – that’s about 300kg per second. As an active, long-term investor,
with sustainable investing in our DNA, we want to play an active role in
combatting the scourge of plastic pollution, a common cause we share
with The Sea Cleaners. Together, we can help protect the oceans for
future generations.
“This partnership is something we are passionate about for two
reasons: firstly, it resonates with a critical part of our value
proposition for clients, reflecting our desire to take a truly holistic
approach to investing sustainably: and secondly, the joint journey will
provide new ways for our colleagues and clients to engage with a topic
that we know they care about a great deal.”
Yvan Bourgnon, President-Founder of The Sea Cleaners, said:
“Ocean plastic pollution is an ecological catastrophe and we are
delighted to make this partnership with AllianzGI, because their values
and sustainability scope are very closely aligned with ours. Innovation,
international and long-term action, sustainable development,
biodiversity protection, education: let’s put people back at the heart
of important ecological challenges. We are proud to work on this
exciting mission and to build together a story about saving the oceans
with a partner like AllianzGI.”
As part of a drive to reduce plastic use across its global business,
AllianzGI is running internal campaigns to reduce its use of single-use
plastics including introducing ‘Plastic Free Tuesdays’ in its London
office, while colleagues have also taken part in beach clean-up
exercises at Baker Beach in San Francisco, Lamma Island in Hong Kong and
Taiwan’s ‘Coastal Cleanup’. AllianzGI’s Hong Kong office was recently
awarded the “Hong Kong Green Organisation Certification” in recognition
of its active participation in adopting various environmental practices,
including reducing its use of plastics, and promoting a green workplace.
AllianzGI is a pioneer in Sustainable investing. For the last two years,
AllianzGI has received an A+ for its overarching approach to ESG
Strategy and Governance from the Principles for Responsible Investment
(PRI). AllianzGI recently appointed Beatrix Anton-Groenemeyer as its
first Chief Sustainability Officer. This new role, which reports
directly to CEO Andreas Utermann, further underscores the importance of
sustainability to AllianzGI and its clients.
All of AllianzGI’s EUR 535bn of Assets under Management are ESG
(Environmental, Social & Governance) informed, with AllianzGI’s
highly-developed, active programme of engagement, stewardship and
proprietary research available to all investment professionals across
AllianzGI. AllianzGI is committed to, and in the process of, embedding
ES&G factors across all of its investment strategies, with Integrated
ESG already applicable to EUR 118bn of the assets AllianzGI manages. In
addition, as well as managing EUR 22bn in dedicated SRI strategies,
AllianzGI manages around EUR 6bn of impact investments.
About Allianz Global Investors
Allianz Global Investors is a leading active asset manager with over 770
investment professionals in 25 offices worldwide and managing more than
EUR 535 billion in assets for individuals, families and institutions*.
Active is the most important word in our vocabulary. Active is how we
create and share value with clients. We believe in solving, not selling,
and in adding value beyond pure economic gain. We invest for the long
term, employing our innovative investment expertise and global
resources. Our goal is to ensure a superior experience for our clients,
wherever they are based and whatever their investment needs.
Active is: Allianz Global Investors
*Data as at 31 March 2019
About The Sea Cleaners
Created in 2016 by the skipper Yvan Bourgnon, The Sea Cleaners is a
general interest association looking after the preservation of the
oceans. The Sea Cleaners teams are dedicated to the reduction of plastic
pollution, and they have a preventive and corrective vision, acting both
on land and at sea. To succeed in this challenge, they have launched an
innovative project : The Manta ship will be the first ocean going vessel
capable of collecting and mass-treating floating ocean waste before it
breaks up. Observer Member of the UN Environment, and supported by the
Albert Foundation of Monaco, the association The Sea Cleaners has set
objectives that revolve around four areas : Environment, Circular
economy, Education and Science.
Disclaimer
Environmental, Social and Governance (ESG) strategies consider factors
beyond traditional financial information to select securities or
eliminate exposure which could result in relative investment performance
deviating from other strategies or broad market benchmarks.
Investing involves risk. The value of an investment and the income from
it will fluctuate and investors may not get back the principal invested.
Past performance is not indicative of future performance. This is a
marketing communication. It is for informational purposes only. This
document does not constitute investment advice or a recommendation to
buy, sell or hold any security and shall not be deemed an offer to sell
or a solicitation of an offer to buy any security.
The views and opinions expressed herein, which are subject to change
without notice, are those of the issuer or its affiliated companies at
the time of publication. Certain data used are derived from various
sources believed to be reliable, but the accuracy or completeness of the
data is not guaranteed and no liability is assumed for any direct or
consequential losses arising from their use. The duplication,
publication, extraction or transmission of the contents, irrespective of
the form, is not permitted.
This material has not been reviewed by any regulatory authorities. In
mainland China, it is used only as supporting material to the offshore
investment products offered by commercial banks under the Qualified
Domestic Institutional Investors scheme pursuant to applicable rules and
regulations. This communication’s sole purpose is to inform and does not
under any circumstance constitute promotion or publicity of Allianz
Global Investors products and/or services in Colombia or to Colombian
residents pursuant to part 4 of Decree 2555 of 2010. This communication
does not in any way aim to directly or indirectly initiate the purchase
of a product or the provision of a service offered by Allianz Global
Investors. Via reception of his document, each resident in Colombia
acknowledges and accepts to have contacted Allianz Global Investors via
their own initiative and that the communication under no circumstances
does not arise from any promotional or marketing activities carried out
by Allianz Global Investors. Colombian residents accept that accessing
any type of social network page of Allianz Global Investors is done
under their own responsibility and initiative and are aware that they
may access specific information on the products and services of Allianz
Global Investors. This communication is strictly private and
confidential and may not be reproduced. This communication does not
constitute a public offer of securities in Colombia pursuant to the
public offer regulation set forth in Decree 2555 of 2010. This
communication and the information provided herein should not be
considered a solicitation or an offer by Allianz Global Investors or its
affiliates to provide any financial products in Panama, Peru, and
Uruguay.
This document is being distributed by the following Allianz Global
Investors companies: Allianz Global Investors U.S. LLC, an investment
adviser registered with the U.S. Securities and Exchange Commission;
Allianz Global Investors Distributors LLC, distributor registered with
FINRA, is affiliated with Allianz Global Investors U.S. LLC; Allianz
Global Investors GmbH, an investment company in Germany, authorized by
the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin);
Allianz Global Investors (Schweiz) AG, licensed by FINMA (www.finma.ch)
for distribution and by OAKBV (Oberaufsichtskommission berufliche
Vorsorge) for asset management related to occupational pensions in
Switzerland; Allianz Global Investors Asia Pacific Ltd., licensed by the
Hong Kong Securities and Futures Commission; Allianz Global Investors
Singapore Ltd., regulated by the Monetary Authority of Singapore
[Company Registration No. 199907169Z]; Allianz Global Investors Japan
Co., Ltd., registered in Japan as a Financial Instruments Business
Operator [Registered No. The Director of Kanto Local Finance Bureau
(Financial Instruments Business Operator), No. 424, Member of Japan
Investment Advisers Association and Investment Trust Association,
Japan];and Allianz Global Investors Taiwan Ltd., licensed by Financial
Supervisory Commission in Taiwan. 864007
Contacts
Alastair Fairbrother
Tel. 44 020 3246 7432
Sarah Einig
Tel. 44 020 3246 7846
Vivi McDuell
Tel. 44 020 3246 7251
Email: [email protected]
David Taieb
Tel 33 661 558 401
Email: [email protected]
Antoine Rodat
Tel 33 664 626 958
Email: [email protected]
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.
“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”
Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.
“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”
Arbel holds a BA and MBA from Tel Aviv University.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
[email protected]
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html
Indivior
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
- Primary and Secondary End Points of the Study were Not Met
- Indivior Does Not Currently Expect to Exercise AEF0117 Option
SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ — Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma’s announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD.
The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD.
This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option.
Important Cautionary Note Regarding Forward-Looking Statements
This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding whether: we will be able to ultimately demonstrate the safety and efficacy of AEF0117, which is a prerequisite to filing any New Drug Application; we might ever exercise our option for AEF0117 and, if so, when; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” “guidance,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those because they relate to future events. Various factors may cause differences between Indivior’s expectations and actual results, including, among others, the risks described in our most recent annual report on Form 20-F beginning on page 9 as filed with the U.S. SEC and in subsequent releases; legal and market restrictions that may limit how quickly we can repurchaser our shares; the substantial litigation and ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs; risks related to the manufacture and distribution of our products, most of which contain controlled substances; market acceptance of our products as well as our ability to commercialize our products and compete with other market participants; competition; the uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process; our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry; unintended side effects caused by the clinical study or commercial use of our products; our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions; our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights; the risks related to product liability claims or product recalls; the significant amount of laws and regulations that we are subject to, including due to the international nature of our business; macroeconomic trends and other global developments such as armed conflicts and pandemics; the terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due; changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets; and volatility in our share price due to factors unrelated to our operating performance or that may result from the potential move of our primary listing to the U.S.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.
This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References:
- National Library of Medicine (U.S.) (2022, April). Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2). Identifier
NCT05322941 https://www.clinicaltrials.gov/study/NCT05322941
Logo – https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237355.html
